SAN CARLOS, Calif., Nov. 6, 2015 /PRNewswire/ -- Rosa & Co. LLC, the leading commercial drug development advisory firm with expertise in Quantitative Systems Pharmacology (QSP)/PhysioPD™, today announced their participation and presentation of a poster at the 2015 Roche Pharma Research and Early Development (pRED) Symposium held on November 2-3rd, 2015 in New York City. Rosa's poster was entitled "Model qualification approaches for quantitative systems pharmacology and mechanistic physiological models."
Dr. Christina Friedrich, Chief Engineer at Rosa, attended the Symposium and presented the poster comparing several recently proposed qualification approaches, including Rosa's Model Qualification Method (MQM), to identify common themes and analyze differences. Model qualification is a topic of acute interest in the QSP community, and the MQM was developed to ensure that QSP models are fit for purpose and support actionable research insights.
The symposium entitled "Increasing Drug Development Success: Understanding Drug-Disease Interactions through Quantitative Systems Pharmacology" was designed to bring together key global leaders in QSP to explore how to leverage the interfaces of theoretical and experimental pharmacology to improve drug development efficiency. In recent years, QSP has emerged as a powerful research approach that enables scientific insight and informs early discovery to clinical development decisions. The most innovative R&D organizations in the industry are increasingly adopting QSP as an essential research component for more informed decision-making. Rosa's participation in this symposium further demonstrates its commitment to expanding the adoption of QSP into a standard research method used within the pharmaceutical industry.
"We are pleased to see increasing acceptance of the vital role QSP can play in informing drug development decisions. We are also proud to be taking a leading role in defining methodologies and standards for QSP model qualification."
-Dr. Ron Beaver, Founder, Chairman, and CEO, Rosa & Co. LLC
Rosa supports clients with their critical decisions – from preclinical through clinical development – by creating and using customized PhysioPD™ Research Platforms that connect mechanisms to outcomes. PhysioPD Platforms are used to simulate normal and disease physiology, drug action, patient variability, and trial outcomes. Rosa's clients are involved in Platform creation, testing, and biological simulation research. Clients retain the Platform as a program asset to support decisions and future research. Rosa's staff has unparalleled professional experience applying biological modeling and simulation research to accelerate drug development and has over 13 years of client engagements in virtually all therapeutic areas. Rosa is unique in its breadth and depth of disease area experience, including metabolic diseases, immuno-oncology, oncology, cardiovascular, inflammation, immune dysfunction, central nervous system disorders, dermatology, and antibacterial/antiviral biology. For more information, visit http://www.rosaandco.com/news.html.
Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rosa--co-presented-a-poster-at-the-2015-roche-pharma-research-and-early-development-pred-symposium-300173998.html
SOURCE Rosa & Co.